CTLT vs. UTHR, ROIV, VKTX, SRPT, ASND, LEGN, RDY, CERE, KRTX, and JAZZ
Should you be buying Catalent stock or one of its competitors? The main competitors of Catalent include United Therapeutics (UTHR), Roivant Sciences (ROIV), Viking Therapeutics (VKTX), Sarepta Therapeutics (SRPT), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Dr. Reddy's Laboratories (RDY), Cerevel Therapeutics (CERE), Karuna Therapeutics (KRTX), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceutical preparations" industry.
United Therapeutics (NASDAQ:UTHR) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.
94.1% of United Therapeutics shares are held by institutional investors. 12.5% of United Therapeutics shares are held by insiders. Comparatively, 0.3% of Catalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
United Therapeutics currently has a consensus price target of $308.78, suggesting a potential upside of 17.67%. Catalent has a consensus price target of $52.46, suggesting a potential downside of 7.15%. Given Catalent's stronger consensus rating and higher possible upside, equities research analysts plainly believe United Therapeutics is more favorable than Catalent.
United Therapeutics has higher earnings, but lower revenue than Catalent. Catalent is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Catalent received 72 more outperform votes than United Therapeutics when rated by MarketBeat users. However, 61.67% of users gave United Therapeutics an outperform vote while only 59.37% of users gave Catalent an outperform vote.
In the previous week, United Therapeutics had 25 more articles in the media than Catalent. MarketBeat recorded 32 mentions for United Therapeutics and 7 mentions for Catalent. Catalent's average media sentiment score of 0.95 beat United Therapeutics' score of 0.58 indicating that United Therapeutics is being referred to more favorably in the media.
United Therapeutics has a net margin of 42.05% compared to United Therapeutics' net margin of -29.91%. Catalent's return on equity of 18.72% beat United Therapeutics' return on equity.
United Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.
Summary
United Therapeutics beats Catalent on 15 of the 18 factors compared between the two stocks.
Get Catalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalent Competitors List
Related Companies and Tools
